Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Avacta Group PLC

Healthcare GB AVCT

70.0GBX
0.00(0%)

Last update at 2026-06-04T15:35:00Z

Day Range

69.0074.00
LowHigh

52 Week Range

26.0084.00
LowHigh

Fundamentals

  • Previous Close 70.00
  • Market Cap321.99M
  • Volume1920759
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-29.40000M
  • Revenue TTM0.11M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.11M
  • Diluted EPS TTM-0.11

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -28.98300M -31.12500M -41.64200M -29.19400M -21.34300M
Minority interest - - - - -
Net income -52.84100M -24.94700M -39.54000M -26.37400M -18.89100M
Selling general administrative 12.05M 2.91M 2.29M 8.14M 7.32M
Selling and marketing expenses 12.05M 7.89M 11.23M 8.14M 7.32M
Gross profit 0.11M 2.84M 7.24M 2.02M 2.18M
Reconciled depreciation 1.44M 3.67M 3.01M 2.38M 2.15M
Ebit -19.12900M -15.40900M -27.82000M -29.08300M -19.33500M
Ebitda -17.62400M -14.11700M -25.86900M -26.69000M -17.35500M
Depreciation and amortization 1.50M 1.29M 1.95M 2.39M 1.98M
Non operating income net other - - - - -
Operating income -32.55800M -22.00500M -27.82000M -29.08300M -19.33500M
Other operating expenses 32.67M 25.98M 37.47M 32.02M 22.97M
Interest expense 10.09M 15.30M 2.70M 0.13M 0.09M
Tax provision 0.44M -2.37000M -2.10200M -2.82000M -2.45200M
Interest income 0.66M 0.66M 0.09M 0.02M 0.04M
Net interest income -9.42800M -14.64300M -2.61000M -0.11100M -0.05000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.44M -2.37000M -2.10200M -2.82000M -2.45200M
Total revenue 0.11M 2.85M 9.65M 2.94M 3.64M
Total operating expenses 32.67M 25.97M 35.06M 31.10M 21.52M
Cost of revenue 1.50M 0.01M 2.41M 0.92M 1.46M
Total other income expense net 3.58M -9.12000M -13.82200M -0.11100M -2.00800M
Discontinued operations - - - 0.06M 0.06M
Net income from continuing ops -29.42700M -24.94700M -39.54000M -26.37400M -18.89100M
Net income applicable to common shares - - - -26.31600M -18.89100M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 48.27M 73.19M 92.65M 47.00M 67.46M
Intangible assets 0.30M 13.80M 12.09M 6.39M 7.10M
Earning assets - - - - -
Other current assets 23.95M 4.33M - 8.36M 5.09M
Total liab 38.99M 51.39M 74.21M 5.78M 5.53M
Total stockholder equity 9.28M 21.80M 18.44M 41.22M 61.93M
Deferred long term liab - - - 6.05M 6.87M
Other current liab 12.91M 22.77M 39.10M 0.35M 2.40M
Common stock 36.94M 28.50M 26.68M 25.47M 25.34M
Capital stock 36.94M 28.42M 26.68M 25.39M 25.27M
Retained earnings -138.82900M -85.75300M -65.99700M -34.09300M -12.86100M
Other liab - - - - -
Good will 1.54M 17.04M 14.23M 1.54M 2.31M
Other assets - - - 6.05M 6.87M
Cash 12.87M 16.63M 41.78M 26.19M 27.89M
Cash and equivalents - - - - -
Total current liabilities 37.30M 45.11M 67.61M 4.37M 3.78M
Current deferred revenue - 0.30M - - -
Net debt 10.06M 6.89M -17.93800M -24.48800M -25.85200M
Short term debt 21.45M 17.56M 20.09M 0.29M 0.29M
Short long term debt 20.50M 16.26M 18.73M - -
Short long term debt total 22.93M 23.51M 23.84M 1.70M 2.04M
Other stockholder equity 113.21M 80.73M 57.75M 49.84M 49.45M
Property plant equipment - - - 4.34M 4.79M
Total current assets 40.20M 28.04M 55.55M 34.74M 53.25M
Long term investments - - - - -
Net tangible assets - - - 33.30M 59.38M
Short term investments - - - - 20.02M
Net receivables 3.38M 4.49M 5.58M 4.33M 4.06M
Long term debt 0.00000M 0.22M - - -
Inventory 0.00000M 2.58M 1.68M 0.19M 0.25M
Accounts payable 2.80M 3.73M 8.42M 3.73M 3.49M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -2.04300M -1.67800M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 25.34M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.44M 0.25M 2.98M 7.92M -0.00100M
Deferred long term asset charges - - - - -
Non current assets total 8.07M 45.16M 37.10M 12.27M 14.21M
Capital lease obligations 2.44M 7.03M 5.11M 1.70M 2.04M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -1.43100M -9.00100M -25.04200M 18.70M -20.23400M
Change to liabilities - - 0.00000M 0.46M 1.63M
Total cashflows from investing activities -1.43100M -9.00100M - 18.70M -21.89900M
Net borrowings -2.55000M 0.00000M - -0.29000M -0.25500M
Total cash from financing activities 26.09M -1.29800M 56.90M 0.23M 51.65M
Change to operating activities - - - - -
Net income -29.42700M -24.94700M -39.18900M -26.31600M -18.89100M
Change in cash 1.15M -25.15400M 15.59M -1.70300M 19.11M
Begin period cash flow 16.63M 41.78M 26.19M 27.89M 8.79M
End period cash flow 17.78M 16.63M 41.78M 26.19M 27.89M
Total cash from operating activities -23.59700M -14.87200M -16.43200M -20.50600M -10.64200M
Issuance of capital stock 31.88M 0.40M 9.49M 0.52M 54.86M
Depreciation 1.44M 3.67M 3.01M 2.38M 2.15M
Other cashflows from investing activities -1.10800M 0.02M - - -
Dividends paid - - - - -
Change to inventory - 0.20M 0.05M 0.01M -0.09100M
Change to account receivables -0.24400M 0.84M - -1.59900M -0.81400M
Sale purchase of stock - - - - -
Other cashflows from financing activities -3.23100M -1.45000M 47.42M -0.29000M -3.21500M
Change to netincome - - 15.88M 4.61M 5.37M
Capital expenditures 0.34M 1.26M 0.76M 1.31M 1.67M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.31M 0.74M 3.87M -1.13000M 0.72M
Stock based compensation 4.11M 2.91M 7.49M 5.08M 3.11M
Other non cash items -0.03400M 2.76M 8.38M 0.12M 0.05M
Free cash flow -23.93600M -16.13400M -17.19100M -21.82000M -12.30700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AVCT
Avacta Group PLC		 - -% 70.00 - - 2849.46 1929.84 2525.51 -12.0368
GNS
Genus PLC		 38.00 1.70% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 5.50 4.09% 140.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 28.00 4.90% 600.00 - 208.33 4.05 7.60 4.42 308.96
IBT
International Biotechnology Trust plc		 28.00 2.99% 966.00 - 714.29 16.40 1.20 15.60

Reports Covered

Stock Research & News

View All

Profile

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.

Avacta Group PLC

Scale Space White City Imperial College Campus, London, United Kingdom, W12 7RZ

Key Executives

Name Title Year Born
Dr. David Alastair Smith CEO & Exec. Director NA
Mr. Tony Gardiner CFO, Company Sec. & Exec. Director 1971
Ms. Emma Wright Group In-House Counsel NA
Mr. Michael Vinegrad Group Communications Director NA
Dr. Matt Johnson Chief Scientific Officer of Diagnostics NA
Dr. Neil Bell Chief Devel. Officer of Therapeutics 1958
Dr. Fiona McLaughlin FSB, Ph.D. Chief Scientific Officer of Therapeutics Division 1970
Mr. Marc Green Head of Product Devel. - Diagnostics NA
Gemma Wilson Head of QA/RA - Diagnostics NA
Mr. Petros Sarantos Head of Product Management - Diagnostics NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.